{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:14:53Z","timestamp":1790626493692,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clinthera.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T08:15:48Z","timestamp":1598688948000},"page":"2084-2097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events"],"prefix":"10.1016","volume":"42","author":[{"given":"Paul P.","family":"Dobesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon W.","family":"Finks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby C.","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.08.003_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and epidemiologic drivers of global cardiovascular mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"vol. 385","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.003_bib3","series-title":"Projections of Cardiovascular Disease Prevalence and Costs: 2015-2035","author":"Nelson","year":"2016"},{"key":"10.1016\/j.clinthera.2020.08.003_bib4","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib5","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib7","first-page":"1","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization. The task force on myocardial revascularization of the European society of Cardiology (ESC) and European association for cardio-thoracic surgery (EACTS)","author":"Neumann","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2020.08.003_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11239-015-1306-3","article-title":"Dual pathway therapy in acute coronary syndrome","volume":"42","author":"Stachon","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.clinthera.2020.08.003_bib9","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib10","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2020.08.003_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.recesp.2015.06.016","article-title":"The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization","volume":"69","author":"Abu-Assi","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed"},{"key":"10.1016\/j.clinthera.2020.08.003_bib12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.CIR.0000140721.27004.4B","article-title":"Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trial","volume":"110","author":"Cutlip","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2020.08.003_bib13","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.115.021158","article-title":"Individualizing duration of dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention","volume":"133","author":"Bagai","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2020.08.003_bib14","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib15","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004139","article-title":"Dual antiplatelet therapy continued beyond 1 year after drug-eluting stents: a meta-analysis of randomized trials","volume":"10","author":"Ferrante","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.clinthera.2020.08.003_bib18","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.003_bib20","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","article-title":"Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial","volume":"49","author":"Bhatt","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2020.08.003_bib22","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2017.07.768","article-title":"Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54","volume":"70","author":"Bonaca","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","article-title":"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial","volume":"394","author":"Bhatt","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.003_bib26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11883-017-0654-1","article-title":"New-generation coronary stents: current data and future directions","volume":"19","author":"Kalra","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2020.08.003_bib27","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2020.08.003_bib28","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin. The randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2020.08.003_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"Nakamura","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.clinthera.2020.08.003_bib30","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.003_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2020.08.003_bib32","first-page":"365","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"Helft","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2020.08.003_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcin.2015.10.001","article-title":"Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents","volume":"9","author":"Hermiller","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"key":"10.1016\/j.clinthera.2020.08.003_bib34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib35","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in patients with high-risk PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2020.08.003_bib36","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2020.08.003_bib37","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2020.08.003_bib38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/eurheartj\/ehw683","article-title":"Personalising the decision for prolonged dual antiplatelet therapy: development, validation, and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors","volume":"38","author":"Pasea","year":"2017","journal-title":"Eur Heart J"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820303544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:47Z","timestamp":1758963287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820303544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0149291820303544"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}